ReviewJournal of clinical medicine2025

Rituximab, Apremilast, and Upadacitinib as Selected Biosimilar and Targeted Synthetic Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action: Their Current Use in Slowing Down the Progression of Disease.

Piotr Kawczak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.